

For Immediate Release

US Department of Defense Renews Contract with Cytomatrix

16th FEBRUARY 2005, SINGAPORE – Leading global stem cell technology and immunotherapy company, CyGenics, Ltd. (ASX: CYN), today announced that the US Department of Defense had exercised its option to renew its contract with its Boston-based subsidiary, Cytomatrix LLC. Under the original award in December 2003, Cytomatrix received a contract valued at \$1,684,000 for a two year screening service programme. This amount was partially funded for the first year at US\$618,000. The US Government has now fully funded the original award amount to be able to complete the second year of the contract.

The contract makes use of the company's patented T cell production technology, in which its three-dimensional cell growth scaffold facilitates the production of T cells from stem cells outside the human body for the first time. This unique system can be utilised by the DOD to screen vaccine prototypes under development. By employing this *in vitro* system, researchers have been able to assess how the human immune system will respond to proposed vaccines, thus determining which are most likely to be effective *in vivo*.

“To the best of our knowledge, this is the first time such an approach to vaccine development has been used anywhere in the world,” said Dr Michael Michalek, Director Cellular Screening Services, Cytomatrix. “This approach reduces both the cost and the time taken to bring vaccines to market, in particular, reducing the use of animals in the early stages of vaccine testing, as well as often laborious assays using donated human samples. For some vaccines, this could result in savings of years of effort and millions of dollars.”



About CyGenics

CyGenics is a stem cell technology and immunotherapy company focused on the development and commercialisation of stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development), based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

Ronald Hee	Rod Nockles
Corporate Communications & Marketing Manager	Director
CordLife Pte Ltd	Financial & Corporate Relations
600 North Bridge Road,	Level 20,
#12-09/10, Parkview Square,	114 William Street
Singapore 188778, Singapore	Melbourne Victoria 3000
	Australia
Tel : +65 6238 0808	Tel: +61 3 9670 7996
Fax : +65 6295 1108	Fax: +61 3 9670 3883
Mobile: +65 9061 9098	Mobile: +61 (0) 419 691 323
Email: rhee@cordlife.com	E-mail: r.nockles@fcr.com.au